A recent phase 1 trial (NCT02359565) has shown that children with hypermutated high-grade gliomas and mismatch repair deficiency derive clinical benefit from immune checkpoint blockade with a programmed cell death protein 1 (PD-1) inhibitor [70]. Here, PDCD1 is linked to glioma.